PLSH (Panacea Life Sciences Holdings) EV-to-EBIT: 1.35 (As of Jul. 11, 2026)


What is Panacea Life Sciences Holdings EV-to-EBIT?

Panacea Life Sciences Holdings PLSH -28.57% EV-to-EBIT is 1.35 as of Jul. 11, 2026. The stock has 6 warning signs investors should review. Among 689 Drug Manufacturers companies, Panacea Life Sciences Holdings ranks better than 95.36% on this metric.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Panacea Life Sciences Holdings's Enterprise Value is $2.35 Mil. Panacea Life Sciences Holdings's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 was $1.74 Mil. Therefore, Panacea Life Sciences Holdings's EV-to-EBIT for today is 1.35.

The historical rank and industry rank for Panacea Life Sciences Holdings's EV-to-EBIT or its related term are showing as below:

PLSH' s EV-to-EBIT Range Over the Past 10 Years
Min: -6.83   Med: -3.64   Max: 51.23
Current: 1.35

During the past 4 years, the highest EV-to-EBIT of Panacea Life Sciences Holdings was 51.23. The lowest was -6.83. And the median was -3.64.

PLSH's EV-to-EBIT is ranked better than
95.36% of 689 companies
in the Drug Manufacturers industry
Industry Median: 15.81 vs PLSH: 1.35

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Panacea Life Sciences Holdings's Enterprise Value for the quarter that ended in Sep. 2025 was $1.80 Mil. Panacea Life Sciences Holdings's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 was $1.74 Mil. Panacea Life Sciences Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2025 was 96.47%.

Panacea Life Sciences Holdings  (OTCPK:PLSH) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Panacea Life Sciences Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2025 ) =EBIT / Enterprise Value (Q: Sep. 2025 )
=1.736/1.799576
=96.47 %

Panacea Life Sciences Holdings's Enterprise Value for the quarter that ended in Sep. 2025 was $1.80 Mil.
Panacea Life Sciences Holdings's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Panacea Life Sciences Holdings EV-to-EBIT Related Terms

Panacea Life Sciences Holdings EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for Panacea Life Sciences Holdings's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Panacea Life Sciences Holdings EV-to-EBIT Chart

Panacea Life Sciences Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
0.00 0.00 -2.67 -3.74

Panacea Life Sciences Holdings Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.58 -5.56 -12.53 9.46 1.04

PLSH vs SKYI, IMCC, CBDY: EV-to-EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Panacea Life Sciences Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Panacea Life Sciences Holdings EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Panacea Life Sciences Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Panacea Life Sciences Holdings's EV-to-EBIT falls into.


Panacea Life Sciences Holdings EV-to-EBIT Calculation

Panacea Life Sciences Holdings's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=2.351/1.736
=1.35

Panacea Life Sciences Holdings's current Enterprise Value is $2.35 Mil.
Panacea Life Sciences Holdings's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-EBIT →
What does a EV-to-EBIT of 1.35 mean?
Panacea Life Sciences Holdings (PLSH) has a EV-to-EBIT of 1.35 as of Jul. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Panacea Life Sciences Holdings and its competitors. According to the industry distribution chart, Panacea Life Sciences Holdings ranks #32 out of 689 companies in the Drug Manufacturers industry, placing it in the top 4.6%.
Is Panacea Life Sciences Holdings' EV-to-EBIT too high?
Panacea Life Sciences Holdings' current EV-to-EBIT is 1.35. The Drug Manufacturers industry median EV-to-EBIT is 15.81. Panacea Life Sciences Holdings' value of 1.35 is 91.5% below this industry median. Based on the distribution chart, Panacea Life Sciences Holdings ranks #32 out of 689 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Panacea Life Sciences Holdings' EV-to-EBIT compare to SKYI and IMCC?
According to the Drug Manufacturers industry distribution chart, Panacea Life Sciences Holdings ranks #32 out of 689 companies for EV-to-EBIT. This places Panacea Life Sciences Holdings in the top 5% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.81. Panacea Life Sciences Holdings' value of 1.35 is 91.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.81, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Panacea Life Sciences Holdings's current EV-to-EBIT of 1.35 is 91.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Panacea Life Sciences Holdings and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Panacea Life Sciences Holdings's current EV-to-EBIT is 1.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Life Sciences Holdings stock overvalued right now?
Panacea Life Sciences Holdings (PLSH) has a current EV-to-EBIT of 1.35. The current EV-to-EBIT is 1.35 and 91.5% below the Drug Manufacturers industry median of 15.81. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Panacea Life Sciences Holdings (PLSH), the current EV-to-EBIT is 1.35 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Panacea Life Sciences Holdings Business Description

Address 5910 South University Boulevard, C18-193, Greenwood Village, CO, USA, 80121
Panacea Life Sciences Holdings Inc is a holding company organized as a plant-based natural health ingredient and product company, specializing in the development, manufacturing, research, and distribution of products and rapidly growing natural health and wellness market segment for both humans and animals. The company also offers the purest natural remedies within its branded product lines for every aspect of life: PANA Health, PANA Beauty, PANA Sport, PANA Pet, PANA Pure and PANA Life.